Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
Y KomakiA YamadaF KomakiD MicicA IdoAtsushi SakurabaPublished in: Alimentary pharmacology & therapeutics (2017)
CT-P13 was associated with excellent clinical efficacy and safety profile, supporting its use in the treatment of IBD.